• Stiripentol: LDH Inhibition for Epilepsy and Immunometabolic

  2026-05-03

  Explore how Stiripentol, a novel LDH inhibitor, is redefining translational research by bridging epilepsy models and tumor immunometabolism. This article provides mechanistic insights, experimental best practices, and strategic guidance for researchers leveraging LDH inhibition in metabolic, neurological, and immuno-oncology studies.

• Reliable Pyroptosis Detection with Caspase-4 Colorimetric As

  2026-05-02

  This article addresses laboratory challenges in cell viability and pyroptosis studies, showcasing how the Caspase-4 Colorimetric Assay Kit (SKU K2199) from APExBIO delivers reproducible, quantitative LEVD-dependent caspase-4 activity detection. Drawing on published literature and validated protocols, it offers scenario-driven guidance for robust experimental workflows and informed reagent selection.

• Prochlorperazine: Translating Dopamine Antagonism to Cancer

  2026-05-02

  This thought-leadership piece explores how Prochlorperazine, a dopamine D2 receptor antagonist, is redefining translational research at the interface of antiemetic therapy, melanoma research, and antiviral discovery. Integrating mechanistic insights, protocol best practices, and a critical appraisal of the competitive landscape, the article provides actionable guidance for researchers aiming to harness Prochlorperazine’s multifaceted pharmacology in preclinical and clinical workflows.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-05-01

  This study introduces a glabridin-gold(I) complex (6d) as a dual-action immunomodulatory agent, targeting thioredoxin reductase (TrxR) and MAPK pathways to synergistically increase antitumor immunity in liver cancer. By promoting dendritic cell maturation and mitigating immunosuppressive cell populations, 6d offers a promising strategy to overcome tumor immune evasion.

• PYR-41: Unlocking Ubiquitin Pathways for Translational Impac

  2026-04-30

  Explore how PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, empowers translational researchers to dissect protein degradation, modulate NF-κB signaling, and advance disease models. This thought-leadership article bridges mechanistic insight and strategic guidance, highlighting evidence from cancer immunology to inflammation, and positions APExBIO’s PYR-41 as an essential research tool beyond standard product profiles.

• Mitoxantrone HCl (SKU B2114): Reliable Topoisomerase II Inhi

  2026-04-30

  This article provides an evidence-based, scenario-driven guide for life science researchers evaluating Mitoxantrone HCl (SKU B2114) for cell viability, apoptosis, and cytotoxicity workflows. Grounded in peer-reviewed data and validated protocols, it addresses real laboratory challenges and demonstrates how the compound’s reproducibility, solubility, and mechanistic versatility can optimize experimental outcomes.

• T7 RNA Polymerase: Optimizing In Vitro Transcription for RNA

  2026-04-29

  T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, enables high-yield, sequence-specific RNA synthesis crucial for cutting-edge applications like RNA vaccine production and in situ lung cancer immunotherapy. This article details protocol enhancements, troubleshooting, and translational insights, guiding researchers from bench to advanced RNA workflows with proven tools from APExBIO.

• Nile Red: Precision Lipid Droplet Imaging for Autophagy Insi

  2026-04-29

  Explore how Nile Red (Nile blue oxazone) empowers advanced intracellular lipid droplet staining and lipid metabolism research, with a unique focus on integrating autophagy assay decisions. This article delivers technical depth and practical guidance distinct from existing resources.

• AI-Driven Discovery of Novel Senolytics for Targeted Cell Cl

  2026-04-28

  This study applies machine learning to identify new senolytic compounds capable of selectively eliminating senescent cells, significantly reducing screening costs and expanding therapeutic options for cancer and age-related diseases. The computational framework demonstrates robust validation in diverse cellular models, highlighting the power of AI in early-stage drug discovery.

• EZ Cap™ Firefly Luciferase mRNA: Advancing Bioluminescent As

  2026-04-28

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure drives high-sensitivity, reproducible gene regulation and translation efficiency assays in mammalian cells. Its advanced design and stability set a new benchmark for in vitro and in vivo bioluminescent reporter workflows, supporting robust mRNA delivery and imaging applications.

• Leupeptin Hemisulfate Salt: Precision in Protease Regulation

  2026-04-27

  Leupeptin hemisulfate salt empowers researchers to precisely regulate protease activity in protein degradation and viral replication studies. This guide translates the latest protocol innovations—including metabolite binding workflows—into actionable steps, troubleshooting tactics, and comparative insights for advanced biochemical research.

• Antipyrine in High-Throughput BBB Models: New Horizons in CN

  2026-04-27

  Discover how Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) uniquely advances high-throughput blood-brain barrier (BBB) modeling and CNS drug development. This article provides a deeper scientific analysis grounded in the latest permeability prediction research.

• Pam3CSK4 as a TLR1/2 Agonist: Workflow, Applications, and Tr

  2026-04-26

  Pam3CSK4 enables precise activation of TLR1/2, unlocking detailed insights into immune cell signaling and neuro-immune modulation. This guide details robust assay design, workflow optimization, and troubleshooting strategies for advanced inflammation and allergy models.

• Cyclo (-RGDfC): Precision αvβ3 Integrin Targeting in Cancer

  2026-04-25

  Cyclo (-RGDfC), a cyclic RGD peptide, enables high-specificity targeting of the αvβ3 integrin receptor, central to tumor angiogenesis and metastasis. Its enhanced stability and affinity make it a benchmark reagent in cancer research and integrin-mediated cell assays.

• Pomalidomide (CC-4047) in Hematological Malignancy Research

  2026-04-24

  Pomalidomide (CC-4047) stands out as a precision immunomodulatory tool for dissecting tumor microenvironment complexity and overcoming resistance in hematological malignancy models. This guide offers optimized protocols, troubleshooting strategies, and translational insights for leveraging CC-4047 in advanced myeloma and erythroid differentiation research.

16195 records 1/1080 page Next 12345 下5页 Last page